Endometriosis Treatment Market to Peg US$ 4 Bn in 2030
Tech-driven advancements in non-invasive treatment, and molecular diagnostics have been on-ramp to material shifts in the healthcare vertical over the past few decades. Moreover, they have been playing a tremendous role in effectively addressing all sorts of gynecological disorders. Endometriosis impacts around 200 million females across the world. The worldwide value pool of the endometriosis treatment market will cross US$ 4 Bn by 2030. Manufacturers of endometriosis drugs are focused on developing non-invasive diagnostic technologies in order to prevent late diagnosis and patient discomfort.
Frequently Asked Questions about Endometriosis Treatment Market
Will rise in the prevalence of endometriosis affect the growth of the endometriosis treatment market?
In the past few years, there has been a surge in the total number of endometriosis cases across the world. This unnoticed endometriosis is now coming under the lenses of healthcare communities and national authorities. This has resulted in increasing demand for novel therapeutics for endometriosis treatment.
How will advancements in non-invasive diagnostic technologies change the treatment adoption rate?
In developed economies such as the U.S. and Europe, are extensive research studies have been completed and a majority are ongoing for the early diagnosis of endometriosis. Body fluid bio-markers and genomics test kits will be expected to significantly accelerate the early diagnosis and subsequent treatment of endometriosis.
How will novel therapeutic development surge the growth of the endometriosis treatment market in the near future?
Big global pharmaceutical and biopharmaceutical giants are investing extensively in the research & development of new drug entities, new indications of existing drugs, and/or novel drug delivery for endometriosis. These focused scientific activities are expected to meet the unmet need of endometriosis treatment by increasing the availability of superior therapeutics for patients.
Which type of drug has better growth potential over the next decade?
Oral contraceptives are expected to witness relatively high demand, owing to advancements in the scientific efficacy and proven safety of this drug type. Also, Gonadotropin-releasing hormone (GnRH) analogues are widely accepted with new therapeutic launches in this segment.
Which region will offer the most lucrative opportunities for endometriosis treatment market players?
The market in Europe and North America is expected to witness significant growth over the forecast period, owing to rising awareness and early diagnosis in the U.S., Germany, and other European countries. In developing countries, India, China and Brazil remain the top three target geographies for leading manufacturers to expand their regional presence.
Oral Contraceptive Drugs Capture Around 50% Value Share
Oral contraceptives are highly preferable as a first-line treatment for patients without contraindications, on grounds of their efficacy in preventing recurrence of pelvic pain and endometriosis lesions. However, they are associated with possible side effects such as mood changes, nausea, and elevated blood pressure levels. Progestins, on the other hand, require to be consumed periodically, unlike oral contraceptives, which require regular consumption. By 2029, the drug category will represent a billion-dollar opportunity. Furthermore, market players are unlocking new revenue streams in gonadotropin-releasing hormone (GnRH) analogues for relevant value creation.
Opportunities Prevail in Developed Regions
Europe and North America will maintain their supremacy in the global endometriosis treatment market, with the latter expected to cross US$ 1 Bn in 2020. Incumbents are pairing with healthcare providers to raise awareness in the field of endometriosis at physician and patient levels. While these developed regional markets maintain a positive trend, stakeholders are eyeing Asia for further revenue lines. Governments in China and India are significantly increasing their healthcare budgets in order to reach the unmet sections of society.
* This data is only a representation. Actual data may vary and will be available in report.
Advanced Drug Delivery Technologies to Propel Market Growth
Oral contraceptives have been the conventional drug category for treating endometriosis. Yet, they carry the drawback of first-pass liver metabolism. Market players are rolling out novel transdermal drug delivery technologies such as topical applicators to enhance efficacy and overcome the disadvantages of oral contraceptives. Moreover, these advanced drug delivery technologies achieve steady serum hormone concentration, and thus, are expected to become commonplace in endometriosis treatment. For instance, Noven has developed CombiPatch®, a combination (two-drug) patch that can be effectively used in endometriosis treatment.
Oral contraceptives stay atop
Progestins on gradual rise
Hormonal therapy remains preferable treatment type
Pain management to gain momentum
Hospital pharmacies hold leading value proportion
Retail pharmacies to showcase higher CAGR
How Growth will Unfold
Market player continue to bank on hormonal therapy to stay ahead of their peers in the endometriosis treatment market. FMI finds that, around 9 out of 10 medical professionals prefer hormonal replacement therapy for treating endometriosis, attributable to its enhanced effectiveness with minimum risks of breast cancer. That being said, patients undergoing the treatment are subject to post-therapy complications such as bloating, indigestion, and leg cramps. As such, they are turning to other options, including pain management.
* This data is only a representation. Actual data may vary and will be available in report.Click Here To Know How The Growth Will Unfold
Custom Market Research Services
FMI offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.
A recent market study published by Future Market Insights (FMI) on the endometriosis treatment market includes global industry analysis of 2014-2018 and opportunity assessment for 2019-2030, and delivers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historical as well as current growth parameters of the endometriosis treatment market, the growth prospects of the market are obtained with maximum precision.
The report features unique and salient factors that may have a huge impact on the development of the endometriosis treatment market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in landscape in the coming years. The report provides detailed information about the current and future growth prospects of the endometriosis treatment market in the most comprehensive way for the better understanding of readers.
Endometriosis Treatment Market Taxonomy
The global endometriosis treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
- Oral Contraceptives
- GnRH Analogues
- Hormonal Therapy
- Pain Management
- Hospital Pharmacies
- Retail Pharmacies
- North America
- Latin America
- South Asia
- East Asia
- Middle East and Africa (MEA)
The report commences with the executive summary of the endometriosis treatment market, which includes the summary of key findings and statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the endometriosis treatment market as well as the key trends impacting the market.
Readers can find the definition and detailed segmentation of the endometriosis treatment market in this chapter. Along with, this section also highlights the inclusions and exclusions, which help the reader understand the scope of the endometriosis treatment market report.
This section gives information about the key trends impacting the endometriosis treatment market.
This section explains the key success factors of the market including new product launches, clinical developments, regulatory scenario, product adoption, application analysis, reimbursement scenario, regulatory approvals and what are the key strategies followed by the manufacturers for the growth of the market.
This section explains the global market value analysis and forecast for the endometriosis treatment market during the forecast periods of 2019-2030. Along with that, it includes historical endometriosis treatment market and opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2019), and an incremental $ opportunity for the forecast period (2019-2030).
This section provides regional level pricing of the product that is manufacturer level pricing and distributor level pricing.
This section includes major factors influencing the market and various drivers, restraints and opportunities of the market.
Based on drug, the endometriosis treatment market is segmented into oral contraceptives, progestins, NSAIDs, GnRH analogues, LNR-IUDs, and others.
Based on treatment type, the market is segmented into hormonal therapy and pain management.
Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, drugstores, and e-Commerce.
This chapter explains how the endometriosis treatment market will grow across various geographic regions such as North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa (MEA).
This chapter includes a detailed analysis of the growth of the North America endometriosis treatment market, along with a country-wise assessment that includes the U.S. and Canada. Readers can also find the regional trends, and market growth based on drug type, treatment type, distribution channel, and countries in North America.
This chapter provides the growth scenario of the endometriosis treatment market in Latin American countries such as Brazil, Mexico, Argentina and the Rest of Latin America. Along with this, an assessment of the market across target segments has been provided.
Important growth prospects of the endometriosis treatment market based on its end-users in several countries such as the Germany, Italy, France, the U.K., Spain, Russia and the Rest of Europe are included in this chapter.
Important growth prospects of the endometriosis treatment market based on its end-users in several countries such as India, Thailand, Indonesia, Malaysia and the rest of South Asia are included in this chapter.
In this chapter, China, Japan and South Korea are the prominent countries in East Asia that are the prime subjects of assessment to obtain the growth prospects of the endometriosis treatment market. Readers can find detailed information about the growth parameters of the endometriosis treatment market during the forecast period of 2019-2030.
This section highlights the growth prospects of the endometriosis treatment market for Australia and New Zealand, during the forecast period of 2019-2030.
This chapter provides information about how the endometriosis treatment market will grow in major countries in the MEA region such as GCC Countries, South Africa, UAE, Saudi Arabia, Turkey and the Rest of MEA, during the forecast period of 2019-2030.
This section highlights the growth prospects of the endometriosis treatment market for the emerging countries such as China, India and Brazil.
This chapter provides information about the market structure analysis by tier of companies. Readers can find a detailed analysis of market concentration and market presence by the regional footprint of players, product footprint by players and channel footprint by players.
In this chapter, readers can find a comprehensive list of all prominent stakeholders in the endometriosis treatment market, along with detailed information about each company, which includes company overview, revenue shares, strategic overview, and recent company developments. Some of the market players featured in the report are AbbVie Inc., Bayer AG, Pfizer Inc., Astrazeneca Plc., Debiopharm Group, Amneal Pharmaceuticals, Inc., Noven Pharmaceuticals, Inc., Endoceutics, Inc., Myovant Sciences Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., and Sun Pharmaceutical Industries Limited
This chapter includes a list of acronyms and assumptions that provides a base to the information and statistics included in the endometriosis treatment market report.
This chapter help readers understand the research methodology followed to obtain various conclusions as well as important qualitative and quantitative information about the endometriosis treatment market.
How the research was conducted?
- C - Level Executives
- Marketing Directors
- Product Managers
- Business Development Officers
- Production Managers
- Procurement Heads
- Sales Executives
- Raw Material Suppliers
- Industry Experts
- End Users
- Current Market Dynamics and Challenges
- Yesteryear Trends
- Market Characteristics
- Market Performance and Growth Quadrants
- Competition Structure and Market Structure
- Strategic Growth Initiatives
- Near-term and Long-term Market Growth Prospects
- Market Segment Splits and Authenticity
- Opinions on Market Projections and Validity of Assumptions
- Industry Publications
- World Health Organizations (WHO)
- National Institute of Health (NIH)
- Company Press Releases
- Annual Reports and Investor Presentations
- Research Papers
- Government Websites and Publications
- Trade Websites
Primary Interview Splits